Latest Breaking News On - Rafaelg amado - Page 1 : comparemela.com

Repotrectinib Receives NMPA Approval in China for ROS1+ NSCLC

Repotrectinib Receives NMPA Approval in China for ROS1+ NSCLC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Rafaelg amadoDrug administrationZai labChina national medical products administrationLung cancer center at shanghai chest hospitalShanghai jiaotong universityGlobal oncology researchBristol myers squibbNational medical products administrationLung cancer centerShanghai chest hospitalGreater china

Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs

SHANGHAI & CAMBRIDGE, Mass., April 02, 2024 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that two poster presentations highlighting ongoing global clinical studies in its oncology pipeline will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024, in San Diego, California.

United statesSan diego convention centerSan diegoChristine chiou lina zhangLinda liuRafaelg amadoAmerican association for cancer researchExchange commissionHead of global oncology researchZai lab forwardZai labZai lab limitedZai lab phaseAmerican associationCancer researchAnnual meeting

Bristol-Myers Squibb (BMY) Announces KRYSTAL-12 Confirmatory Trial of KRAZATI Meets Primary Endpoint

Bristol-Myers Squibb (BMY) Announces KRYSTAL-12 Confirmatory Trial of KRAZATI Meets Primary Endpoint
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Bristol myers squibbRafaelg amadoZai lab limitedNational medical products associationZai labHead of global oncology researchBlinded independent central reviewGlobal oncology researchMyers squibbNew drug applicationPrescription drug user fee act

Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic

Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesBristol myers squibbRafaelg amadoWorld health organizationNational medical products associationRegulatory agencyZai lab limitedExchange commissionEuropean commissionHead of global oncology researchZai labZai lab forwardTrial evaluatingMeets primary endpointProgression free survivalMutated locally advanced

Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

SHANGHAI & CAMBRIDGE, Mass. (BUSINESS WIRE) Mar 13, 2024

Czech republicUnited statesChristine chiou lina zhangLindan liuRafaelg amadoOrgilmma regzedmmaJennifer chang xiaoyu chenZai lab forwardPrague congress centreEuropean lung cancer congressExchange commissionCongress hall foyerZai labGlobal oncology researchZai lab limitedLab limited